Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing can feel like decoding a medical journal—especially when MBX Biosciences packs its 10-K with pages of pharmacokinetic data on its PEP platform and tables of Phase 1 safety results. If you are searching “MBX SEC filings explained simply” or wondering how the company’s R&D spend aligns with upcoming trial milestones, you are not alone. Investors need quick clarity on how precision peptide programs translate into shareholder value.
Stock Titan delivers that clarity by pairing every MBX document—whether a quarterly earnings report 10-Q filing or an 8-K material event—with AI-powered summaries that turn dense scientific and accounting language into plain English. Our engine flags key passages on cash runway, licensing deals, and clinical-trial endpoints, while real-time alerts surface MBX Form 4 insider transactions the moment executives buy or sell shares. You will also find side-by-side views of historical 10-K risk factors, MBX proxy statement executive compensation details, and S-1/A capital-raising terms, all linked to easy-to-read AI notes.
Use the platform to: track “MBX quarterly earnings report 10-Q filing” trends, monitor “MBX Biosciences insider trading Form 4 transactions,” and dig into pipeline disclosures without spending hours in EDGAR. Want a quick take on the long-acting parathyroid hormone program? Our AI highlights dosing frequency changes. Need “MBX 8-K material events explained” the day they post? You will get instant context plus historical comparables. From “MBX annual report 10-K simplified” breakdowns of R&D tax credits to “MBX earnings report filing analysis” that pinpoints cash burn, every disclosure is covered—so you can focus on decisions, not page counts.
MBX Biosciences, Inc. (MBX) disclosed a new equity award to a director. On 11/22/2025, the director received a stock option to purchase 8,000 shares of common stock at an exercise price of $27.08 per share, reported as a derivative security in Table II.
The option covers 8,000 underlying shares of common stock and is held directly by the reporting person. According to the footnote, the grant will vest in equal monthly installments over a one-year period from November 6, 2025, conditioned on the non-employee director continuing to provide services to the company.
MBX Biosciences (MBX) reported a director stock option grant. On November 6, 2025, the director received 100,000 stock options with an exercise price of $24.74. The options vest in equal monthly installments over one year from the grant date, contingent on continued service. The award expires on November 5, 2035. Following the grant, the reporting person held 100,000 derivative securities, reported as Direct (D) ownership.
MBX Biosciences filed an S-3 shelf registration to offer, issue and sell up to $400,000,000 of securities from time to time. The filing also includes a sales agreement prospectus supplement for an at-the-market program to sell up to $150,000,000 of common stock through Jefferies LLC, which is included within the $400,000,000 shelf capacity.
Sales may occur on a continuous or delayed basis, with specific terms set in future supplements. The company states that net proceeds will be used for development of clinical-stage programs, discovery R&D, additional clinical development, and general corporate purposes, including working capital and capital expenditures.
MBX’s common stock trades on the Nasdaq Global Select Market under “MBX.” The last reported sale price was $20.62 per share on November 4, 2025. Shares outstanding were 44,715,498 as of September 30, 2025.
MBX Biosciences (MBX) filed its Q3 2025 10‑Q, highlighting a stronger balance sheet after a September underwritten offering. The company reported a net loss of $21.6 million for the quarter as operating expenses rose with pipeline advancement. Research and development was $19.3 million and general and administrative was $4.7 million, reflecting continued clinical activity.
Liquidity improved materially: cash, cash equivalents and marketable securities were $391.7 million as of September 30, 2025, supported by the September 2025 offering of 11,108,055 shares at $18.00 for $187.4 million in net proceeds. Total assets were $400.1 million and stockholders’ equity was $387.5 million.
Pipeline updates: canvuparatide met the primary endpoint in Phase 2; the company plans End of Phase 2 interactions in Q1 2026 and a Phase 3 start in Q3 2026. MBX 4291 is in Phase 1 for obesity, and imapextide showed positive Phase 1 results with a Phase 2a in progress. Shares outstanding were 44,715,498 as of September 30, 2025; 44,902,302 as of November 3, 2025.
MBX Biosciences filed an 8-K noting it furnished a press release announcing financial results for the quarter ended September 30, 2025. The release is provided as Exhibit 99.1 and is furnished, not filed, under Item 2.02.
Under Item 5.02, the company reported governance updates. On October 31, 2025, James M. Cornelius resigned from the Board and as Audit Committee chair; the company stated there was no disagreement with MBX regarding operations, policies or practices. Effective November 6, 2025, director Steven Hoerter was appointed executive chairperson. He will receive chair compensation and an option to purchase 100,000 shares vesting monthly over one year. The Audit Committee now comprises Tiba Aynechi (chair), Steven Hoerter, and Ed Mathers.
MBX Biosciences (MBX) reported an insider transaction by its President & CEO and Director on 10/24/2025. The executive exercised a stock option (Code M) to acquire 182,859 shares of common stock at an exercise price of $3.25 per share. Following the transaction, beneficial ownership stood at 664,256 shares held directly and 468,277 shares held indirectly through a revocable trust. The filing lists 129,708 derivative securities (options) remaining post-transaction. The option began vesting monthly from 11/07/2022 and is scheduled to fully vest by 11/07/2026, with early-exercise permitted subject to an issuer repurchase right.
MBX Biosciences (MBX) reported an insider share purchase by its President & CEO and Director on 10/20/2025. The reporting person bought 20,000 shares of common stock at a weighted average price of $13.6395, with trades executed between $13.60 and $13.6399.
Following the transaction, the filing lists 481,397 shares as directly owned and 468,277 shares as indirectly owned by a trust. The trust is identified as the P. Kent Hawryluk Revocable Trust, with the reporting person serving as trustee.
MBX Biosciences (MBX) reported an insider purchase by a director. On 10/17/2025, a revocable trust of the reporting person acquired 20,000 shares of common stock at $13.2492 per share (Transaction Code P). Following the transaction, 20,000 shares were beneficially owned indirectly by the trust. The filer notes a disclaimer of beneficial ownership beyond any pecuniary interest, as stated in the footnote.
Wellington Management reports ownership of
OrbiMed affiliates report a change in beneficial ownership of MBX Biosciences common stock following an increase in the company's outstanding shares. The filing discloses that OrbiMed Advisors, OrbiMed Capital GP VII and OrbiMed Genesis collectively hold 4,002,887 shares, representing approximately 9.0% of 44,700,281 outstanding shares as stated in the issuer's prospectus. The reduction in reported percentage ownership is due to an increase in shares outstanding rather than a sale by the reporting persons. The filing also summarizes the relationships among the funds, their voting and dispositive authority and limited registration and piggyback rights under an Investors' Rights Agreement.
FAQ
What is the current stock price of MBX Biosciences (MBX)?
What is the market cap of MBX Biosciences (MBX)?
